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Background: High-sensitivity C-reactive protein (hs-CRP) is not only a marker of
inflammation but also a prognostic factor for ischemic stroke. The objective of our study
was to investigative the association between hs-CRP levels and outcomes of patients
with small-artery occlusion (SAO).
Methods: We selected 718 participants diagnosed with SAO (according to Trial
of Org 10172 in Acute Stroke Treatment classification) using the stroke registry of
the Department of Neurorehabilitation of Tianjin HuanHu Hospital. Hs-CRP values at
admission were classified into 3 categories:<0.91mg/L, 0.91 to<2.77mg/L, and≥2.77
mg/L. Patients were divided into two subgroups based on age: the younger subgroup
(<75years) and the elder subgroup (≥75 years). Clinical outcomes were evaluated with
the modified Rankin scale (mRS) 3 months after the onset of stroke. We examined the
relationship between hs-CRP levels at the time of admission and mRS scores using
multivariate logistic regression analysis. We also assessed the association between
hs-CRP levels and patient outcomes according to age.
Results: Among 718 patients with SAO (mean age, 61.7± 11.3 years), median hs-CRP
was 1.54 mg/L. Although 628 patients had a favorable outcome, and 90 patients had a
poor outcome at 3 months after SAO. Compared with the lowest levels of hs-CRP, those
highest levels of hs-CRP (hs-CRP > 2.77 mg/L) were at increased risk of poor outcome
(adjusted odds ratio, 1.917; 95% CI, 1.050–3.500; P = 0.034), and more than twice
the risk of poor outcome among patients in the younger subgroup (adjusted odds ratio,
2.092; 95% CI, 1.079–4.058; P = 0.029). These associations persisted after adjustment
for confounding risk factors. However, hs-CRP levels were not significantly associated
with outcome among patients in the elder subgroup.
Conclusions: Elevated hs-CRP in patients with SAO is an independent predictor of poor
prognosis; however, this association is only present in younger patients (<75 years).
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INTRODUCTION
Strok is an important health issue for individuals and society
(Di Napoli et al., 2005). Ischemic stroke accounts for 70–80%
of all stroke cases and is associated with high mortality and
morbidity rates (Bonita et al., 2004). In terms of the Trial of
Org 10172 in Acute Stroke Treatment (TOAST), small-artery
occlusion (SAO) is a subtype of cerebral infarction. SAO, which
is caused by occlusion of the deep branch arteries, accounts
for 25% of ischemic stroke cases and occurs deep in the white
matter, basal ganglia, or pons (Lavallée et al., 2013). Although
the pathophysiology of cerebral small vessel disease is not clear,
increased age, and hypertension and endothelial dysfunction are
considered themain risk factors (vanDijk et al., 2005;Wada et al.,
2008; Lavallée et al., 2013).
There is increasing evidence that elevated high-sensitivity
C-reactive protein (hs-CRP) is a risk factor as well as a prognostic
factor for ischemic stroke and coronary events (Rifai and
Ridker, 2001; Di Napoli et al., 2005; Ishikawa et al., 2007; den
Hertog et al., 2009; Song et al., 2009). Hs-CRP is a sensitive
marker of inflammation and tissue injury in the arterial wall
(Pearson et al., 2003; Pfützner and Forst, 2006). An hs-CRP assay
quantifies small incremental changes in inflammation, which
may bemore clinically relevant comparedwith C-reactive protein
for assessing the relationship between acute inflammation and
predicting the degree of long-term disability (VanGilder et al.,
2014). Although many studies have demonstrated that hs-CRP
may affect ischemic stroke patients’ outcomes, the association
between hs-CRP and outcomes following SAO has not been
established, especially among elderly patients diagnosed with
SAO. Therefore, the aim of the present study was to investigate
the association between hs-CRP levels and SAO outcomes
according to patients’ ages.
MATERIALS AND METHODS
Subjects
This study was approved by the ethics committee of Tianjin
Huanhu Hospital and met the principles set forth in the
1964 Declaration of Helsinki and its later amendments or
comparable ethical standards. An written informed consent
was obtained from the participants and their families at the
beginning of the study. All patients were screened according
to a strict protocol consisting of complete medical history,
full neurological examination, standardized blood tests, imaging
examination, and a cardiac analysis that included standard 12-
lead echocardiography. Detailed baseline data were collected and
abstracted using electronic-based record forms during patients’
hospitalization.
This study utilized a hospital-based registry of consecutive
patients with stroke who visited the Department of
Neurorehabilitation of Tianjin HuanHu Hospital between
October 25, 2012 and June 30, 2015. There were 2818 cases of
ischemic stroke diagnosed within 7 days of stroke onset; among
these, 1837 were diagnosed with non-SAO, 180 patients had no
hs-CRP data, and 83 patients were lost to follow-up. Finally, 718
patients with SAO met the inclusion criteria and were analyzed
in this study (Figure 1). Finally, patients were classified into
two subgroups according to age (younger subgroup, <75 years,
n = 613; elder subgroup, ≥75 years, n = 105).
Diagnostic Criteria of SAO
The most widely applied classification is the TOAST subtype
classification, which categorizes stroke into five etiological
subtypes (Fromm et al., 2016), one of which is SAO. This
category includes stroke cases that are often labeled as lacunar
infarcts in other classification systems (Bamford et al., 1987). The
diagnostic criteria of SAO are as follows: patients were required
to have one of the traditional clinical lacunar syndromes with
no evidence of cerebral cortical dysfunction; the infarction was
required to have been located in the subcortex or brain stem
and be <1.5 cm in diameter on computed tomography/magnetic
resonance imaging; a history of diabetes mellitus or hypertension
supported the clinical diagnosis; and patients were required to
have no potential cardiac sources for embolism and stenosis no
greater than 50% in an ipsilateral artery (Adams et al., 1993).
Stroke cases were classified by two neurologists.
Hs-CRP and Clinical Assessment
Blood samples were collected from the cubital vein of each patient
before breakfast in the early morning within 24 h of admission
(3.7± 2.1 days after symptom onset) (VanGilder et al., 2014). Hs-
CRP assays were performed using immunoturbidimetric assay.
Hs-CRP levels were classified into three groups: < 0.91 mg/L
(n = 236), 0.91 to < 2.77 mg/L (n = 243), and ≥2.77 mg/L (n =
239). We conducted a laboratory calibration study to evaluate
possible differences in the hs-CRP measurements between
laboratories, specimen types, assay methods, instruments, and
time of measurement, and found that the differences in hs-CRP
were not large enough to warrant calibration.
Baseline information, including sex, age, and complete
medical history, were recorded for each patient at admission;
fasting glucose level, total cholesterol level, and other indicators
were measured within 24 h of admission using a certified
central laboratory. According to the Joint National Committee
VI–VII, hypertension was defined as systolic blood pressure
>140mmHg and/or diastolic blood pressure >90mmHg,
based on the average of two blood pressure measurements,
or a patient’s self-reported history of hypertension or anti-
hypertensive medication use, supported by documents (Munshi
et al., 2008). Diabetes mellitus was diagnosed if the fasting
plasma glucose level was >110 mg/dl or if the patient was taking
anti-diabetic medications. Dyslipidemia was defined as either
receiving treatment with cholesterol-reducing agents or a high-
density lipoprotein cholesterol level≤1.04mmol/L, a triglyceride
level ≥ 2.26 mmol/L, or a total cholesterol level ≥6.22mmol/L.
Patients who smoked tobacco products almost every day for >1
year were defined as current smokers. Patients who consumed
alcohol at least one time per week for >1 year were defined as
current drinkers. Body mass index was measured at the time
of admission, and obesity was defined as a body mass index
≥30 kg/m2 (Wilterdink et al., 2001). An index of severity was
obtained by all patients on the National Institutes of Health
Stroke Scale (NIHSS) (Brott et al., 1989).
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FIGURE 1 | Flow chart of patient selection.
Follow-Up
Follow-up telephone interviews or in-person interviews were
conducted with all the patients at 3 months after stroke onset.
All follow-up results were recorded into the stroke database.
Study Outcome
Clinical outcomes were evaluated with the modified Rankin scale
(mRS) 3 months after the onset of stroke. Patients were divided
into two groups according to median mRS scores. Favorable
outcome was defined as a score of 0–2, and poor outcome was
defined as a score of 3–5. There were no records of patient deaths
during the follow-up period.
Statistical Analysis
The distribution of hs-CRP levels and other risk factors were
evaluated, for all patients and by patient groups. Other risk
factors, such as age, sex, hypertension, diabetes, dyslipidemia,
alcohol consumption, smoking status, obesity, and NIHSS score,
were included in the univariate analysis as confounding factors.
The relationship of hs-CRP levels with stroke outcomes was
evaluated using multiple logistic regression analysis, which
included confounding variables that were identified as significant
(P < 0.05) in the univariate analysis.
Continuous variables are expressed as means ± standard
deviations or tertiles. Differences between groups were analyzed
for statistical significance using t-tests and one-way analysis
of variance. Nominal variables were expressed as proportions.
Differences in nominal variables between groups were assessed
by using the chi-square test or Fisher’s exact test. All tests were
two sided and P-values < 0.05 were considered statistically
significant. Statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS 17.0).
RESULTS
Baseline Demographics and Clinical
Characteristics According to hs-CRP
Stratifications
Between October 25, 2012 and June 30, 2015, 718 patients (502
men [69.9%]; range, 30–83 years) diagnosed with SAO were
identified. The baseline demographics and clinical characteristics
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of patients are presented in Table 1. NIHSS scores ranged from
1 to 14. The median (quartiles) hs-CRP values of all patients
was 1545 mg/L (0.70, 3.71 mg/L). The median (quartiles) hs-CRP
values of the three hs-CRP groups [<0.91 mg/L (n = 236), 0.91
to <2.77 mg/L (n = 243), and ≥2.77 mg/L (n = 239)] were 0.50
mg/L (0.32, 0.69 mg/L), 1.54 mg/L (1.22, 2.00 mg/L), and 5.24
mg/L (3.71, 10.00 mg/L), respectively. Hypertension, diabetes,
and obesity were more prevalent in the group with the highest
hs-CRP levels; however, the prevalence of alcohol drinkers was
lowest in the group with the highest hs-CRP levels. Lower
high-density lipoprotein cholesterol levels and higher HbA1c
levels were associated with patients with the highest hs-CRP
levels.
Comparison of the Risk Factors between
Different Groups Classified by Outcomes
Patients were divided into two groups according to mRS scores:
the favorable outcome (score of 0–2) and poor outcome (score of
3–5) groups (Table 2). Risk factors, including age, sex, diabetes
mellitus, smoking status, alcohol consumption, hs-CRP levels,
and NIHSS scores, were significantly different between groups
(P < 0.001, P < 0.028, P < 0.041, P < 0.008, P < 0.010,
P < 0.003, and P < 0.001, respectively). During hospitalization,
22 patients developed infectious diseases (12 respiratory tract
infections, 8 urinary tract infections, and two other infections),
including 18 patients (2.9%) with favorable outcome and five
patients (4.4%) with poor outcome. There was no statistical
association in the distribution between the two parts (P = 0.627).
Patients were also classified into two subgroups according to age
[younger subgroup, <75 years (n = 613); elder subgroup, ≥75
years (n = 105)]. Sex, smoking status, alcohol consumption were
significantly different between the younger subgroups with and
without a favorable outcome (P < 0.045, P < 0.043, P < 0.034,
respectively). Meanwhile, compared with unfavorable outcomes
patients, patients with favorable outcomes were more likely have
lower hs-CRP levels, and NIHSS scores in the younger subgroups
(P < 0.024 and P < 0.001, respectively). However, hs-CRP
levels between patients with and without a favorable outcome
were not significantly different in the elder subgroups (P =
0.185).
Multivariate Logistical Regression
Analyses of hs-CRP Groups and Outcome
Among all patients, compared to the lowest hs-CRP group,
the highest hs-CRP group was independently associated with
poor outcome at 3 months in the multivariate analysis, after
adjusting for age, sex, diabetes mellitus, smoking status, alcohol
consumption, and NIHSS score (adjusted odds ratio, 1.917; 95%
CI, 1.050–3.500; P = 0.034; Table 3). However, the middle hs-
CRP group (0.91 to < 2.77 mg/L) was not associated with poor
outcome (P = 0.673). In the younger subgroup, compared
with the lowest hs-CRP group, the highest hs-CRP group was
also independently associated with poor outcome at 3 months
in the multivariate analysis, after adjusting for sex, smoking
TABLE 1 | Baseline demographics and clinical characteristics according to hs-CRP groups.
Groups of hs-CRP mg/L
<0.91 (n = 236) 0.91 to <2.77 (n = 243) ≥2.77 (n = 239)
Age, years (median values)* 59.17 ± 10.75 61.37 ± 11.16 64.27 ± 11.44
Male sex, n(%) 175 (74.2) 163 (67.1) 164 (68.6)
RISK FACTORS
Hypertension, n(%)* 163 (69.1) 185 (76.1) 198 (82.8)
Dyslipidemia, n(%) 62 (26.3) 72 (29.6) 61 (25.5)
Diabetes, n(%)* 83 (35.2) 119 (49.0) 125 (52.3)
Smokers, n(%) 108 (45.8) 83 (34.2) 92 (38.5)
Alcohol drinkers, n(%)* 57 (24.2) 40 (16.5) 38 (15.9)
Obesity, n(%)* 16 (6.8) 30 (12.3) 37 (15.5)
LABORATORY FINDINGS
TC,mmol/L (median values)* 4.91 ± 0.95 4.82 ± 0.88 5.23± 2.89
TG,mmol/L (median values) 1.74 ± 1.12 1.66 ± 0.94 1.80 ± 1.14
HDL-C,mmol/L (median values)* 1.10 ± 0.28 1.05 ± 0.27 1.03 ± 0.24
LDL-C,mmol/L (median values) 2.94 ± 0.75 2.95 ± 0.69 3.08 ± 0.92
HbA1c,mmol/L (median values)* 6.42 ± 1.31 6.61 ± 1.24 6.82 ± 1.44
Hcy media, 25th percentile, 75th percentile) 11.80 (9.72, 15.45) 11.20 (9.38, 16.50) 12.00 (9.67, 17.10)
NIHSS, n(%)
0∼6 193 (81.8) 197 (81.1) 183 (76.6)
≥7 43 (18.2) 46 (18.9) 56 (23.4)
*Indicates P< 0.05 when comparing between three groups. TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
HbA1c, hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; Hcy, homocysteine; NIHSS, National Institute of Health stroke scale.
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TABLE 2 | Comparison of the risk factors between different groups classified by outcomes.
Total (n = 718) ≤75 (n = 613) ≥75 (n = 105)
mRS ≤ 2 mRS ≥ 3 p-value mRS ≤ 2 mRS ≥ 3 p-value mRS ≤ 2 mRS ≥ 3 p-value
(n = 628) (n = 90) (n = 550) (n = 63) (n = 78) (n = 27)
Age, years (median values) 60.93 ± 11.01 66.38 ± 12.21 <0.001 58.39 ± 9.17 60.21 ± 8.78 0.134 78.87 ± 3.79 80.78 ± 4.27 0.032
Male sex, n(%) 448 (71.3) 54 (60.0) 0.028 406 (73.8) 69 (61.9) 0.045 42 (53.8) 15 (55.6) 0.878
Hypertension, n(%) 476 (75.8) 70 (77.8) 0.680 420 (76.4) 49 (77.8) 0.802 56 (71.8) 21 (77.8) 0.545
Dyslipidemia, n(%) 174 (27.7) 21 (23.3) 0.383 158 (28.7) 14 (22.2) 0.276 16 (20.5) 7 (25.9) 0.558
Diabetes, n(%) 277 (44.1) 50 (55.6) 0.041 245 (44.5) 34 (54.0) 0.155 32 (41.0) 16 (59.3) 0.101
Smokers, n(%) 259 (41.2) 24 (26.7) 0.008 248 (45.1) 20 (31.7) 0.043 11 (14.1) 4 (14.8) 0.927
Alcohol drinkers, n(%) 127 (20.2) 8 (8.9) 0.010 125 (22.7) 7 (11.1) 0.034 2 (2.6) 1 (3.7) 0.759
Obesity, n(%) 68 (10.8) 15 (16.7) 0.105 58 (10.5) 7 (11.1) 0.890 10 (12.8) 8 (29.6) 0.046
Hcy (media, 25th
percentile,75th percentile)
11.60 (9.63,
15.80)
12.20 (9.11,
17.50)
0.471 11.60 (9.53,
15.6)
11.70 (8.90,
20.03)
0.668 11.95 (10.20,
16.08)
13.00 (10.08,
16.50)
0.862
hs-CRP, n(%) 0.003 0.024 0.185
<0.91 216 (34.4) 20 (22.2) 199 (36.2) 17 (27.0) 17 (21.8) 3 (11.1)
0.91 to <2.77 217 (34.6) 26 (28.9) 190 (34.5) 17 (27.0) 27 (34.6) 9 (33.3)
≥2.77 195 (31.1) 44 (48.9) 161 (29.3) 29 (46.0) 34 (43.6) 15 (55.6)
NIHSS, n(%) <0.001 <0.001 0.036
0∼6 527 (83.9) 46 (51.1) 472 (85.8) 33 (52.4) 55 (70.5) 13 (48.1)
≥7 101 (16.1) 44 (48.9) 78 (14.2) 30 (47.6) 23 (29.5) 14 (51.9)
mRS, modified Rankin scale; hs-CRP, hypersensitive C-reactive protein; NIHSS, National Institute of Health stroke scale.
status, alcohol consumption, and NIHSS score (adjusted odds
ratio, 2.092; 95% CI, 1.079–4.058; P = 0.029); the middle hs-
CRP group (0.91 to <2.77 mg/L) was not associated with poor
outcome (P = 0.961). However, in the elder subgroup, hs-
CRP level was not associated with outcome after adjusting for
risk factors (i.e., age, obesity, and NIHSS score) identified as
significant in the univariate analysis (P = 0.341 and P = 0.263,
respectively).
DISCUSSION
We evaluated patient information using a hospital-based stroke
registry from Tianjin, northern China. To the best of our
knowledge, this is the first study that has aimed to assess the
association between plasma hs-CRP levels and 3month outcomes
among SAO patients in northern China. Compared with those
patients from southern China, our patients have lower age (61 vs.
69 years), lower plasma hs-CRP levels (1.55 vs. 3.35 mg/L), more
Diabetes (45.5 vs. 19.14%) (Lv et al., 2016).
In our study, elevated hs-CRP levels in patients with SAO
was an independent predictor of poor prognosis 3 months
after SAO; however, this association was only present in the
younger subgroup. In line with our findings, the Circulatory
Risk in Communities Study reported a positive association
between hs-CRP levels and lacunar stroke in Japanese men
and women (Chei et al., 2011). Rajeshwar et al. (2012) and
Ladenvall et al. (2006) found no significant association between
CRP levels and the prognosis of patients with lacunar infarcts
after 3 months. These contradictory findings may result from
differences in sample sizes, patient race, patient age, methods
used to evaluate disease, and analytic strategies. Moreover,
advanced age, hypertension, diabetes, alcohol consumption,
obesity, total cholesterol levels, lower high-density lipoprotein
cholesterol levels, and higher HbA1c levels were associated
with elevated hs-CRP levels (Latha and Chandrakala Shenoy,
2008; Wada et al., 2008; Jiang et al., 2009; Chaudhuri et al.,
2013). This is in accordance with the findings of the current
study.
In this study, elevated hs-CRP levels were associated with
prognosis in younger patients but not in older patients. Although
the pathophysiological link between cerebral small-vessel disease
and hs-CRP is not clear, different mechanisms may be involved.
Hs-CRP is a marker of inflammation, and the inflammatory
response plays an important role in patients with SAO; it is
associated with plaque instability, stenosis, or occlusion of the
small vessels (Zeng et al., 2013). On the other hand, CRP
levels may be a marker for arteriolosclerosis or small-vessel
disease, as they are for atherosclerosis. Arteriolosclerosis may
result in lacunar infarcts through vessel occlusion, disturbed
cerebral autoregulation, or increased vascular permeability
(Pantoni and Garcia, 1997). More than one mechanism or
a combination of mechanisms could explain the association
between high CRP levels and SAO. Many studies have
demonstrated that high levels of inflammatory mediators, such
as CRP, may be used as prognostic indicators after lacunar stroke
(Elkind et al., 2014).
In this study, there was no significant association between hs-
CRP and outcome among elderly patients. This may be because
aging is associated with weakened innate and adaptive immunity,
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TABLE 3 | Multivariate logistical regression analyses of hs-CRP groups and the outcome variables.
Total (n = 718) ≤ 75 (n = 614) ≥75 (n = 105)
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value
Age 1.025 (1.002–1.048) 0.032 1.130 (1.009–1.265) 0.035
Male 1.175 (0.701–1.970) 0.541 1.269 (0.684–2.354) 0.449
Diabetes 1.294 (0.803–2.085) 0.289
Smokers 0.882 (0.487–1.598) 0.678 0.829 (0.431–1.595) 0.574
Alcohol drinkers 0.638 (0.273–1.490) 0.299 0.599 (0.244–1.472) 0.264
Obesity 2.902 (0.945–8.919) 0.063
hs-CRP
<0.91 index index index
0.91 to <2.77 1.148 (0.605–2.178) 0.673 2.334 (0.474–2.037) 0.961 2.105 (0.455–9.734) 0.341
≥2.77 1.917 (1.050–3.500) 0.034 2.092 (1.079–4.058) 0.029 2.283 (0.537–9.696) 0.263
NIHSS 4.114 (2.531–6.687) <0.001 5.211 (2.972–9.138) <0.001 2.206 (0.848–5.738) 0.105
mRS, modified Rankin scale; hs-CRP, hypersensitive C-reactive protein; NIHSS, National Institute of Health stroke scale.
both quantitatively and qualitatively (Gao et al., 2014). Although
Matsuo et al found that an elevated plasma hs-CRP levels could
predict poor functional outcome at 3 months, however, odds
ratios for poor functional outcome increased more markedly as
an elevation of plasma hs-CRP levels in younger patients (aged
<70 years) than in those aged over 70 years (Matsuo et al.,
2016). Matsuo et al. study recruited not only SAO patients but
also other TOAST subtype ischemic stroke patients, but in line
with present study that inflammation seems have more marked
effect on stroke patients’ outcome in younger patients. Thus, the
inflammation reaction may have been weak among the elderly
patients included in the present study; similarly, the impact of
inflammation in the pathogenesis of small vessel disease-related
brain lesions seems to be weak among the Japanese elderly (Wada
et al., 2008). Second, the elderly patients are more likely to
be taking statins, aspirin, or NSAIDs on a regular basis, and
this would explain lower inflammatory activity in these patients,
they are potential candidates to attenuate progression of lesions
related to small vessel disease and their consequences (Ridker
et al., 2001). Previous studies by van Dijk et al. (2005) and
Wada et al. (2008) found no significant relationship between
CRP levels and small vessel disease severity in the elderly. The
two previous studies assessed the relationship between CRP
levels and small vessel disease severity in the elderly, but we
assessed the relationship between hs-CRP levels and prognosis of
SAO in the elderly. Furthermore, Wada and colleagues recruited
patients with not only lacunar infarcts but also white matter
hyperintensity (Wada et al., 2008). These lesions are commonly
observed on magnetic resonance imaging scans in elderly people
and are associated with an increased risk of stroke (Vermeer
et al., 2003). Age and ethnicities of patients included in the
studies differed, and hs-CRP levels may vary among races and
ethnic groups (Albert et al., 2004; Khera et al., 2005). Albert
et al. previously reported that median hs-CRP values among
Asian women were significantly lower than those among other
races and ethnic groups in the United States (Albert et al.,
2004).
The present study had certain limitations. First, as all
the subjects were recruited from a group of individuals who
voluntarily participated in the system, the sample population
does not represent the general population of China. Second,
718 patients with SAO were involved in this study and no
death record had been found during the follow-up. In fact, it
is impossible for all the patients to achieve a mortality rate of
zero, although SAO has the lowest mortality rate among stroke
subtypes and we chose a short follow-up period. Therefore, there
may be a selection bias which is inevitable. Third, the timing
of sampling in relation to stroke onset may have impacted our
findings; further prospective studies of the optimal timing of
CRP measurement for use as a prognostic marker after ischemic
stroke are warranted. Although extensive prospective studies are
necessary to establish the link between hs-CRP and small vessel
disease, our study clearly demonstrated the association between
hs-CRP levels and the outcomes of SAO patients according
to age.
CONCLUSION
In the present study, we can conclude that elevated hs-CRP
levels in patients with SAO is an independent predictor of poor
prognosis 3 months after SAO; this association was present in
younger, but not in older patients. The underlying mechanisms
have yet to be determined and our findings await confirmation in
other populations.
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